Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 3SBio Inc.
Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while biosimilars are expected to move into the spotlight.
Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.
Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.
Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.
- Generic Drugs
- Large Molecule
- Other Names / Subsidiaries
- Decade Sunshine Limited
- Decade Sunshine Merger Sub
- Hongkong Sansheng
- Shenyang Sunshine Pharmaceutical Company Ltd
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Zhejiang Wansheng Pharmaceutical Co., Ltd
- Sirton Pharmaceuticals SpA
- Sansheng Guojian Pharmaceutical (Shanghai) Co td